Outside advisers to the U.S. Food and Drug Administration on Friday voted unanimously to recommend regulators authorize a second shot of Johnson & Johnson's COVID-19 vaccine, which is not used in Israel, to better protect Americans who received the one-dose vaccine.
The FDA's Vaccines and Related Biological Products Advisory Committee backed the shots for all J&J recipients aged 18 and older at least two months after their first dose.
The FDA is not bound to follow the advisory panel recommendations, but typically does.
They pointed to the lower levels of virus-neutralizing antibodies it provokes compared to vaccines using messenger RNA (mRNA) technology from Moderna Inc and Pfizer Inc/BioNTech SE.